Jones Ian A, Wilson Melissa, Togashi Ryan, Han Bo, Mircheff Austin K, Thomas Vangsness C
Department of Orthopaedic Surgery, Keck School of Medicine of USC, HCT 1520 San Pablo Street, suite 2000, Los Angeles, CA, 90033, USA.
Department of Preventive Medicine, Keck School of Medicine of USC, 2001 Soto Street, SSB1 318A, Los Angeles, CA, 90033, USA.
BMC Musculoskelet Disord. 2018 Oct 24;19(1):383. doi: 10.1186/s12891-018-2300-7.
Osteoarthritis (OA) is a highly debilitating joint disease that causes progressive, irreversible damage to articular cartilage. OA takes a massive toll on society that has grown in recent decades, but no therapy has been shown to halt or reverse the progression of the disease. The critical need for better treatments and increased interest cellular therapies has spawned a new generation of "minimally manipulated" cell treatments. Autologous adipose tissue injections are among the most controversial of these new treatments. Despite a lack of clinical evidence, adipose tissue injections are often marketed as "stem cell" injections with wide-ranging regenerative benefits. The purpose of this study is to estimate the effect size of the treatment by comparing the efficacy of autologous fat to hyaluronic acid (HA). As a secondary aim, we will test for preliminary evidence of efficacy of autologous fat vs. HA.
This is a prospective, single-center, parallel-group, randomized, controlled trial. Participants (n = 54) will receive either a single intra-articular, ultrasound-guided injection of autologous adipose tissue or a single intra-articular, ultrasound-guided injection of HA (1:1 ratio). Outcome data will be obtained at baseline, week-6 and month-6. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain domain (WOMAC-A) will be used as the primary outcome measure. Secondary clinical outcome measures include WOMAC (full), clinical anchors (pain, function, and stiffness), and the 29-point Patient-Reported Outcomes Measurement Information System (PROMIS®) profile. We will also take synovial fluid samples and assess sway velocity using a force plate, as well as analyze excess/discard adipose tissue to gain a better understanding of how intra-articular adipose tissue injections influence the biochemical environment of the joint.
Given the widespread use of intra-articular fat injections in the United States, it is critical that randomized, controlled human studies evaluating efficacy and biological activity be performed. This study is the first step in addressing this unmet need, but it is not without limitations. The most notable limitations of this study are its small size and lack of blinding, which predisposes the study to both investigator and participant bias.
NCT03242707 // HS-17-00365 // Registration Date (First Posted): August 8, 2018.
骨关节炎(OA)是一种极具致残性的关节疾病,会对关节软骨造成渐进性、不可逆的损害。近几十年来,OA给社会带来了巨大负担,但尚无治疗方法能阻止或逆转该疾病的进展。对更好治疗方法的迫切需求以及对细胞疗法兴趣的增加催生了新一代“微创”细胞治疗。自体脂肪组织注射是这些新疗法中最具争议性的方法之一。尽管缺乏临床证据,但脂肪组织注射常被作为具有广泛再生益处的“干细胞”注射进行推销。本研究的目的是通过比较自体脂肪与透明质酸(HA)的疗效来估计治疗的效应大小。作为次要目标,我们将检测自体脂肪与HA疗效的初步证据。
这是一项前瞻性、单中心、平行组、随机对照试验。参与者(n = 54)将接受单次关节内超声引导下的自体脂肪组织注射或单次关节内超声引导下的HA注射(比例为1:1)。在基线、第6周和第6个月获取结局数据。西安大略和麦克马斯特大学骨关节炎指数(WOMAC)疼痛领域(WOMAC - A)将用作主要结局指标。次要临床结局指标包括完整的WOMAC、临床锚定指标(疼痛、功能和僵硬)以及29项患者报告结局测量信息系统(PROMIS®)概况。我们还将采集滑液样本并使用测力板评估摇摆速度,以及分析多余/废弃的脂肪组织,以更好地了解关节内脂肪组织注射如何影响关节的生化环境。
鉴于关节内脂肪注射在美国广泛应用,进行评估疗效和生物活性的随机对照人体研究至关重要。本研究是满足这一未满足需求的第一步,但并非没有局限性。本研究最显著的局限性是样本量小且缺乏盲法,这使得研究容易受到研究者和参与者偏倚的影响。
NCT03242707 // HS - 17 - 00365 // 注册日期(首次发布):2018年8月8日。